The Patent Finder

Jyant Technologies, Inc.

Also on record
Records under this name other than the patents Jyant Technologies, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Back to Jyant Technologies, Inc.

PatentTitleStatus Expires Confidence
US 10,058,093Nanoformulations for Plants
Lapsed on the fee record
Ended Aug 28, 2026 · High confidence
Lapsed on the fee recordEnded Aug 28, 2026High confidence
US 8,796,422Chemokine-Immunoglobulin Fusion Polypeptides, Compositions, Method of Making and Use Thereof
Lapsed on the fee record
Ended Aug 5, 2026 · High confidence
Lapsed on the fee recordEnded Aug 5, 2026High confidence
US 8,231,907Novel Nanoparticles for Delivery of Active Agents
Lapsed on the fee record
Ended Jul 31, 2024 · High confidence
Lapsed on the fee recordEnded Jul 31, 2024High confidence
US 9,249,204Chemokine-Immunoglobulin Fusion Polypeptides, Compositions, Method of Making and Use Thereof
Lapsed on the fee record
Ended Feb 2, 2024 · High confidence
Lapsed on the fee recordEnded Feb 2, 2024High confidence
US 8,512,701ANTI-CXCL13 and ANTI-CXCR5 Antibodies for the Prevention and Treatment of Cancer and Cancer Cell Migration
Term ended
Term ended Jan 24, 2024 · Medium confidence
Term endedTerm ended Jan 24, 2024Medium confidence
US 9,233,120ANTI-CCL25 and ANTI-CCR9 Antibodies for the Prevention and Treatment of Cancer and Cancer Cell Migration
Lapsed on the fee record
Ended Jan 12, 2024 · Low confidence
Lapsed on the fee recordEnded Jan 12, 2024Low confidence
US 8,097,250Anti-Chemokine and Associated Receptors Antibodies for Inhibition of Growth of Neoplasms
Term ended
Term ended Nov 14, 2023 · Medium confidence
Term endedTerm ended Nov 14, 2023Medium confidence
US 8,563,476ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 and ANTI-CXCR5 Agents for Inflammatory Disorders
Term ended
Term ended Nov 14, 2023 · High confidence
Term endedTerm ended Nov 14, 2023High confidence
US 8,658,377Detecting Cancer with ANTI-CCL25 and ANTI-CCR9 Antibodies
Term ended
Ended no later than Nov 14, 2023 · Low confidence
Term endedEnded no later than Nov 14, 2023Low confidence
US 7,964,194Anti-Chemokine and Associated Receptor Antibodies and Uses for Inhibition of Inflammation
Lapsed on the fee record
Ended Jun 21, 2023 · High confidence
Lapsed on the fee recordEnded Jun 21, 2023High confidence
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited